|
|
|
|
IAS 18 |
|
IFRS 15 |
IFRS 15 |
IAS 18 |
IAS 18 |
IFRS 15 |
||
Agreement |
Consideration received |
Consideration received |
Collaboration start date |
Outstanding balance in deferred income as at 31 December 2017 |
Deferred income reclassified from equity following adoption of IFRS 15 |
Outstanding balance in deferred income as at 1 January 2018 |
Revenue recognized, three months ended 31 March 2018 |
Revenue recognized, three months ended 31 March 2018 |
Revenue recognized, three months ended 31 March 2017 |
Outstanding balance in deferred income as at 31 March 2018 |
||
|
(thousands of $) |
(thousands of €) |
|
(thousands of €) |
||||||||
|
||||||||||||
Gilead collaboration agreement for filgotinib – Upfront payment |
300,000 |
275,558 |
January 2016 |
187,449 |
|
187,449 |
20,914 |
20,914 |
13,337 |
166,535 |
||
Gilead collaboration agreement for filgotinib – Subscription agreement(1) |
N.A. |
39,003 |
January 2016 |
26,532 |
|
26,532 |
2,960 |
2,960 |
1,888 |
23,572 |
||
Servier collaboration agreement for osteoarthritis – License fee |
N.A. |
6,000 |
June 2010 |
5,362 |
(5,362) |
– |
|
383 |
|
– |
||
AbbVie collaboration agreement for CF – Upfront payments |
45,000 |
34,001 |
September 2013 |
|
14,872 |
14,872 |
1,950 |
|
|
12,922 |
||
Total upfront and license fees: |
|
219,343 |
9,510 |
228,853 |
25,824 |
24,257 |
15,225 |
203,028 |
||||
|
|
|
|
|
|
|
|
|
|
|
||
Gilead collaboration agreement for filgotinib – Milestone payments |
70,000 |
64,435 |
January 2016 |
|
43,832 |
43,832 |
4,891 |
|
|
38,941 |
||
AbbVie collaboration agreement for CF – Milestone payments |
77,500 |
68,310 |
September 2013 |
|
29,878 |
29,878 |
3,918 |
|
16,564 |
25,960 |
||
Total milestones: |
|
|
– |
73,710 |
73,710 |
8,809 |
– |
16,564 |
64,901 |
|||
Total: |
|
|
219,343 |
83,220 |
302,563 |
34,633 |
24,257 |
31,789 |
267,929 |
|||